Company Overview and News

64
KERX / Keryx Biopharmaceuticals, Inc. 8-K (Current Report)

2018-10-01 sec.gov - 11
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
KERX

57
KERX / Keryx Biopharmaceuticals, Inc. 8-K (Prospectus)

2018-10-01 sec.gov - 4
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
KERX

53
KERX / Keryx Biopharmaceuticals, Inc. null

2018-09-24 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Q(# @;V)J#3P\+TQI;F5A
KERX

55
KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

2018-09-14 sec.gov - 2
425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease September 14, 2018 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals
KERX

54
KERX / Keryx Biopharmaceuticals, Inc. 425 (Prospectus)

2018-09-06 sec.gov - 1
425 Merger of Akebia Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc. Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease September 6, 2018 Filed by Keryx Biopharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Corporation: Keryx Biopharmaceuticals,
KERX

53
KERX / Keryx Biopharmaceuticals, Inc. null

2018-08-21 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0X(# @;V)J#3P\+TQI;[email protected]$O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](&)-C;@<2G4PQ,C S[0;(,C.C$?\8I?P "# #6< ?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV," P(&]B:@T\/"]#(#8Y+T9I;'1E
KERX

53
KERX / Keryx Biopharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-09 sec.gov
Document UNITED STATES
KERX

59
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

2018-08-09 zacks - 1
Keryx Biopharmaceuticals, Inc. (KERX - Free Report) incurred a loss of 18 cents per share in the second quarter of 2018, wider than Zacks Consensus Estimate of a loss of 14 cents. The loss was however, narrower than the year-ago loss of 21 cents.
GD GILD ZTO KERX ILMN AKBA

58
Akebia Therapeutics Inc (AKBA) CEO John Butler on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Good day, ladies and gentlemen. And welcome to the Akebia Therapeutics Second Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. As a reminder, this call is being recorded.
KERX AKBA

53
Keryx Biopharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides

2018-08-08 seekingalpha
The following slide deck was published by Keryx Biopharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings call.
KERX

58
Keryx Biopharmaceuticals, Inc. (KERX) CEO Jodie Morrison on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good morning. My name is Mina and I will be your conference operator today. At this time, I would like to welcome everyone to the Keryx Biopharmaceuticals Conference Call. [Operator Instructions] Thank you.
KERX AKBA

56
Keryx (KERX) Loss Wider Than Expected in Q2, Sales Miss

2018-08-08 zacks
Keryx Biopharmaceuticals Inc. (KERX - Free Report) is a Boston-based biopharmaceutical company working in the field of renal diseases.
VREX ELY IPGP KERX RYB

53
KERX / Keryx Biopharmaceuticals, Inc. 8-K (Current Report)

2018-08-08 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 <
KERX

53
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018

2018-08-02 globenewswire
BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its second quarter 2018 financial results and provide a business update.
KERX

63
What's in Store for ImmunoGen (IMGN) This Earnings Season?

2018-07-25 zacks
ImmunoGen, Inc. (IMGN - Free Report) is scheduled to report second-quarter 2018 results on Jul 27, before market open. In the last reported quarter, the company delivered a negative earnings surprise of 11.11%.
LMT KERX BP DTJ BP.A BP.B BP DTW DTV IMGN BPAQF DTY HZNP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to KERX / Keryx Biopharmaceuticals, Inc. on message board site Silicon Investor.

Keryx Biopharmaceuticals Inc (KERX) Keryx Biopharmaceuticals Inc (KERX) Keryx Biopharmaceuticals Inc (KERX)
CUSIP: 492515101